Table 3. Response, Remission Duration, and Survival After Modified Hyper-CVAD by Pretreatment Characteristics.

Characteristic	No. CR/Total	% CR	P	% 5-Year CRD	P	% 5-Year Survival	P
Age, y			.42		.82		.01
<40	31/34	91		55		59
40-59	16/18	89		41		44
≥60	16/16	100		34		13
Zubrod performance score			.92		.16		.06
0-1	46/50	92		53		50
2	16/17	94		25		24
3	1/1	100		100		100
Hepatomegaly			.52		.53		.37
No	58/63	92		46		42
Yes	5/5	100		60		60
WBC, ×109/L			.13		.12		.62
≤5	30/31	97		53		47
5.1-49.9	22/26	85		42		42
≥50	11/11	100		42		36
Platelet count, ×109/L			.59		.06		.08
<20	8/8	100		15		25
20-80	29/31	94		36		37
>80	26/29	90		69		55
Albumin level, gm/dL			.42		.23		.44
<3	15/17	88		27		41
≥3	48/51	94		55		45
Bilirubin level, mg/dL			.52		.37		.52
<1.3	58/63	92		45		42
>1.3	5/5	100		75		60
FAB classification			.17		.60		.72
L1	16/17	94		29		29
L2	32/32	100		48		46
ND	15/19	79		62		53
Immunophenotype			.65		.35		.21
T lineage	12/13	92		43		31
B lineage	47/49	96		48		48
Precursor	12/12	100		35		33
CALLA	35/37	95		53		51
Karyotype			.69		.54		.34
Diploid	32/35	91		50		49
Other	31/33	94		47		38
Myeloid markers			.10		.71		.89
Positive	23/25	92		41		44
Negative	32/32	100		50		43
CD20 expression ≥20%			.23		.10		.04
Positive	25/25	100		51		51
Negative	32/34	94		39		35
Systemic risk classification			.82		.62		.26
Low	10/11	91		47		63
High	53/57	93		47		40

Hyper-CVAD indicates fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; CR, complete response; CRD, CR duration; WBC, white blood cell count; FAB, French-American-British; ND, not done; CALLA, common acute lymphoblastic leukemia antigen.